Bryce Carmine

Bryce Carmine is an accomplished biotechnology executive with extensive experience in leadership roles across various companies. Currently serving as Chairman and CEO of HaemaLogiX Pty Ltd since March 2015, and as Non-Executive Director of Kazia Therapeutics Limited since June 2015, Bryce has a strong background in developing innovative treatments, particularly for Multiple Myeloma. Prior roles include Chairman, Co-Founder, and Non-Executive Director of HaemalogiX from October 2014 to March 2015, and significant positions at Eli Lilly and Company from April 2005 to December 2011, where responsibilities included global marketing, sales, and product development. Educational qualifications include a Bachelor of Science in Biochemistry, Microbiology, and Genetics from Massey University. Additionally, involvement with the Deans Council for the Indiana University School of Public Policy and Environmental Affairs underscores a commitment to public health and policy.